Abstracts tagged "Collagen-Induced Arthritis"

Abstract Number: 0006 • ACR Convergence 2024
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Mark Noviski¹, Jun Ma¹, Nivetha Brathaban¹, Aishwarya Kumar¹, Dhwani Haria¹, Jenny McKinnell¹, Robert Cass¹, Frederick Cohen¹, Davorka Messmer², Gwenn Hansen¹ and Ryan Rountree¹, ¹Nurix Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Diego, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) mediates signaling downstream of the B cell receptor (BCR), toll-like receptors (TLRs), and Fc receptors (FcRs). This makes BTK an…
Abstract Number: 0080 • ACR Convergence 2024
Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27
Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
Abstract Number: 0296 • ACR Convergence 2024
Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
Laura Mas Sánchez¹, JOSE ELOY OLLER RODRIGUEZ², Elena Grau García³, Carmen Riesco Barcena⁴, SAMUEL LEAL⁵, Marta de la Rubia navarro⁶, Anderson Huaylla Quispe⁷, Pablo Muñoz Martínez⁸, Alba Torrat noves⁹, Daniel Ramos Castro¹⁰, Iago Alcantara Alvarez¹¹, Belén Villanueva Mañés¹¹, Miguel Simeo Vinaixa¹², Andrés Pérez Hurtado¹³ and Jose A Román-Ivorra¹⁴, ¹Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ²HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ³HUP La Fe, Valencia, Spain, ⁴Hospital Universitario i Politecnic La Fe (Valencia-Spain), Valéncia, Spain, ⁵Hospital La Fe, Valencia, Spain, ⁶Rheumatology department, Hospital La Fe, Valéncia, Spain, ⁷Medicina, Valéncia, Spain, ⁸Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁹Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, Valencia, Spain, ¹¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹²Hospital Universitari i Politecnic La Fe, Valencia, Spain, ¹³Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁴Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: There is limited information about musculoskeletal involvement in Marfan syndrome (MS), especially concerning bone metabolism.Methods: We conducted a retrospective and descriptive study of patients…
Abstract Number: 0932 • ACR Convergence 2024
IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Grace Teng¹, Thomas Fung², Annamaria Mocciaro², Ceyda Llapashtica¹, Angie Hammond³, Jesse Gurgel⁴, zhiyu Huang¹, Maria Mouchess¹, Vanessa Gorney⁵, Wesley Minto¹, Sunish Mohanan¹, Adam Schrier¹, Wylie Palmer², Alexandra Borodovsky² and Gundula Min-oo¹, ¹Gilead Sciences, Foster City, CA, ²Nurix Therapeutics, San Francisco, CA, ³Gilead Sciences, Inc., Seattle, WA, ⁴Gilead Sciences, Seattle, CA, ⁵Alterome Therapeutics, San Diego, CA
Background/Purpose: Despite advances in treatment, chronic inflammatory diseases such as rheumatoid arthritis (RA) represent areas of high unmet medical need. IRAK4 is a proximal mediator…
Abstract Number: 0941 • ACR Convergence 2024
DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways
Michal Segal Salto¹, Rebecca Ross², Steven Ferrara³, Kelvin Chan⁴, Elvira haimov⁵, Francesco Del Galdo⁶ and Kulveer Mankia⁶, ¹DeepCure Inc., Tel Aviv, Israel, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³DeepCure Inc., Boston, MA, ⁴DeepCure Inc., Texas, NV, ⁵DeepCure Inc., Los Angeles, CA, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: Bromodomain and Extra-Terminal domain (BET) family proteins (BRD2, BRD3, BRD4, and BRDT) control the transcription of a wide range of proinflammatory and immunoregulatory genes.…
Abstract Number: 1381 • ACR Convergence 2024
Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis
Cécile Bergua¹, Marine Besnard¹, Ghenima Ahmil², Laure-Helene Ouisse², Nadège Vimond¹, Apolline Salama², Bérangère Evrard², Elise Brisebard³, Alexis Collette¹, Fréderic Blanchard⁴, Thibault Larcher³, Ronald Van Brempt¹, Benoit Le Goff⁵, Ignacio Anegon² and Carole Guillonneau¹, ¹AbolerIS Pharma, Nantes, France, Nantes, France, ²Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, ³APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, ⁴INSERM UMR1229, Nantes, France, Nantes, France, ⁵CHU Nantes, France, Nantes, France
Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood…
Abstract Number: 2541 • ACR Convergence 2024
Probiotic Modulation of Gut Microbiota Mitigates Early Rheumatoid Arthritis Progression: Insights from Pre-Clinical Models
Tong Wu¹, Yanhong Li², Yubin Luo¹ and Yi Liu³, ¹West China Hospital, Sichuan University, Cheng Du, China (People's Republic), ²West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, ³West China Hospital of Sichuan University, Chengdu, Sichuan, China
Background/Purpose: Rheumatoid arthritis (RA) progression, categorized by EULAR into six stages, includes pre-clinical RA (Pre-RA)[1], where mucosal surfaces are implicated as initiators of autoimmune responses…
Abstract Number: 1723 • ACR Convergence 2023
3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity
Brendan Allen¹, Sabrina Fechtner², Meagan Chriswell³, Widian Jubair¹, M. Aaron Vrolijk¹, V. Michael Holers⁴ and kristine Kuhn¹, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado Anschutz SOM, Denver, CO, ⁴University of Colorado, Denver, CO
Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
Abstract Number: 1749 • ACR Convergence 2023
Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis
Qi Cheng, Mo chen, Xin chen, Yifan Xie, Yan Du and Huaxiang wu, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…
Abstract Number: 1991 • ACR Convergence 2022
Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation
Siba Raychaudhuri¹, Smriti Raychaudhuri² and Heike Wulff³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, ²VA Medical Center, Sacramento, CA, ³UC Davis, Davis, CA
Background/Purpose: Engagement of the TCR triggers Ca++ influx through Ca++ channels. Ca++ influx is only possible with a counterbalancing K+ efflux through Kv1.3 and/or KCa3.1.…
Abstract Number: 0048 • ACR Convergence 2022
Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice
Elizabeth Ramler¹, Ted Mikuls², Geoffrey Thiele³, Amy Nelson³, Michael Duryee³, Rohit Gaurav³, Todd Wyatt¹, Aaron Schwabb³, carlos hunter³, Bryant England³ and Jill Poole³, ¹University of Nebraska Medical Center, Omaha, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Respiratory-related diseases are among the most common causes of death in rheumatoid arthritis (RA). Although autoimmune diseases are reported in higher frequency in females,…
Abstract Number: 0053 • ACR Convergence 2022
Natural Microbial Exposure Increases Susceptibility of C57BL/6 Mice to Collagen-induced Arthritis
Sahar Lotfi-Emran¹ and David Masopust², ¹University of Minnesota, Minneapolis, MN, ²University of Minnesota, Department of Microbiology and Immunology, Minneapolis, MN
Background/Purpose: Mice exposed to natural microbes (NME) develop an appropriately mature immune system, one that resembles that of a non-neonatal human.1,2 Collagen induced arthritis is…
Abstract Number: 1453 • ACR Convergence 2021
Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The alarmin interleukin (IL)-33 is a member of the IL-1 cytokine family that is rapidly released from the nucleus of a variety of lung…
Abstract Number: 1509 • ACR Convergence 2021
Pharmacological Inhibition of MALT1 Reverses Activation-Induced Metabolic Reprogramming and Ameliorates Autoimmune Pathogenesis in Multiple Animal Models of Chronic Inflammation
Subhabrata Biswas, Mya Steadman, Ynes Helou, Katherine Sellers, Keng Soh, Aditi Chalishazar, Mehmet Badur, Joanna DiSpirito, Brian DeChristopher, John Monroe, Dania Rabah, Barbara Fox and Andy Long, Rheos Medicines, Inc, Cambridge, MA
Background/Purpose: Current therapies for autoimmune and inflammatory diseases generally target select disease nodes, often failing to produce durable clinical remission. Chronic inflammation is associated with…
Abstract Number: 0738 • ACR Convergence 2020
Systemic Administration of Novel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues
Jeffrey Cleland¹, Rishi Sharma², Minghao Sun³, Santiago Appiani La Rosa³ and Rangaramanujam M. Kannan⁴, ¹Ashvattha Therapeutics, Inc, Redwood City, CA, ²Ashvattha Therapeutics, Baltimore, MD, ³Ashvattha Therapeutics, Inc, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Chronic inflammation observed in arthritis and other autoimmune disorders is mediated primarily by pro-inflammatory reactive macrophages. Systemic administration of anti-inflammatory agents does not selectively…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].